Helicos BioSciences Corporation

Helicos Raises $27M In Venture Round

Helicos Raises $27M In Venture Round

February 2, 2004

Firm is latest entrant in tests for genetic data

Stanley N. Lapidus is at it again.

The founder of two Boston-area medical testing companies says he recently completed a $27 million financing round for a new firm he's helped form, called Helicos BioSciences Corp. It will be the latest to enter a field of companies trying to develop tests for genetic data and new ways to study DNA.

Helicos BioSciences Corporation

Helicos BioSciences Launched by Flagship Ventures

Helicos BioSciences Launched by Flagship Ventures

February 2, 2004

Flagship Ventures and Stan Lapidus, whose reputation as a repeat entrepreneur is well known in the biotech industry, have just launched Helicos BioSciences Corporation in Cambridge, MA. Other cofounders and advisors include several of the world's leading academics in the fields of DNA sequencing, cancer research and bioinformatics from Caltech, MIT, Stanford, Harvard and ISB. Stan spent the last 18 months with Flagship as a Venture Partner, helping a number of its portfolio companies grow while searching for a new venture creation challenge.

Acceleron Pharma, Inc.

Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding

Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding

February 13, 2004

BOSTON, MA - February 13, 2004 - Acceleron Pharma, a biopharmaceutical company developing drugs to treat musculoskeletal and metabolic disorders, announced today that it has raised $25 million in its first round of private equity financing. The company has an exceptional team and a set of proprietary approaches that will enable it to develop a deep pipeline of products by targeting a large and high potential family of growth and differentiation factors.

Morphotek, Inc.

Morphotek Inc. Closes $26 Million Series C Financing

Morphotek Inc. Closes $26 Million Series C Financing

February 18, 2004

EXTON, PA - February 18, 2004 - Morphotek Inc. announced today the closing of its $26 million Series C financing, a private placement of preferred stock with existing and new investors, led by Forward Ventures of San Diego, California.

Selventa

Genstruct Appoints Douglas A. Lauffenburger, Ph.D., To Board of Directors

Genstruct Appoints Douglas A. Lauffenburger, Ph.D., To Board of Directors

February 24, 2004

Tuesday, February 24, 2004, 9:00 am ET CAMBRIDGE MA - Genstruct Inc., a biopharmaceutical company that is leading the effort to solve complex biological problems using knowledge modeling and logical simulation, today announced the appointment of Douglas A. Lauffenburger, Ph.D., to its Board of Directors.

BG Medicine, Inc.

Beyond Genomics Appoints Stelios Papadopoulos to its Board of Directors

Beyond Genomics Appoints Stelios Papadopoulos to its Board of Directors

March 2, 2004

WALTHAM, MA - March 2, 2004 - Beyond Genomics, Inc. today announced the appointment of Stelios Papadopoulos, Ph.D., to its Board of Directors. Dr. Papadopoulos is a Vice Chairman of SG Cowen Securities Corporation and an investment banker focused on the biotechnology and pharmaceutical sectors.

Adnexus Therapeutics

Compound Therapeutics, Inc. Announces Acquisition of Strategic Assets of Phylos, Inc.

Compound Therapeutics, Inc. Announces Acquisition of Strategic Assets of Phylos, Inc.

March 9, 2004

A New Generation of Oncology Products to be Advanced in Anti-Angiogenesis Program

WALTHAM, Mass. - March 9, 2004 - Compound Therapeutics, Inc., a biotechnology company leading the development of a new generation of high-potency targeted protein-based drugs, today confirmed details of its acquisition of strategic assets of Phylos, Inc., and announced the advancement of a preclinical oncology program in anti-angiogenesis.

Zalicus

CombinatoRx Raises $30 Million In Third Venture Capital Round

CombinatoRx Raises $30 Million In Third Venture Capital Round

March 10, 2004

Proceeds from Financing to Support Clinical Evaluation of Novel Anti-Inflammatory and Oncology Products

Pervasis Therapeutics, Inc.

A New Attack On Complex Diseases

A New Attack On Complex Diseases

March 15, 2004

By Jeffrey Krasner, Globe Staff, 3/15/2004

Three of the best-known scientists in the field of tissue engineering have teamed up with two leading life-science venture capital firms to launch a company that plans to combine elements of tissue engineering and cell-based therapy with the precision of medical devices to attack a variety of human diseases.

TripAdvisor LLC

IAC Acquires TripAdvisor, Inc.

IAC Acquires TripAdvisor, Inc.

March 16, 2004

Leading Travel Research Site Empowers Consumers with Information and Savings Advice; Will Join IAC Local and Media Services Group

NEW YORK, NY - March 16, 2004 - IAC/InterActiveCorp (Nasdaq: IACI) today announced that the company has agreed to acquire TripAdvisor, Inc., the leading travel research site. Terms of the agreement were not disclosed.